Deerfield
About Deerfield

Launched in 1994, Deerfield Management Company is an investment firm dedicated to advancing healthcare through information, investment, and philanthropy—all toward the end goal of cures for disease, improved quality of life, and reduced cost of care.

Read More
---
Investment

Supporting companies across the healthcare ecosystem with flexible funding models…

Read More
---
Information

Delivering market research to the Deerfield team, its portfolio companies and other partners.

Read More ---
Philanthropy

A New York City-based not-for-profit devoted to advancing innovative health care initiatives.

Read More
---
Portfolio Companies

Deerfield generally maintains a combined portfolio of more than 150 private and public investments across the life science, medical device, diagnostic, digital health and health service industries at all stages of evolution from start-up to mature company.

Read More View Portfolio Companies
---
Research Collaborations

Deerfield partners with leading academic research centers, providing critical funding and expertise to further sustain and accelerate the commercialization of discoveries toward meaningful societal impact by advancing cures for disease.

Read More View Research Collaborations
---
Strategic Partners

As a strategic partner, Deerfield offers capital, scientific expertise, business operating support, and unique access to innovation.

Read More
---
Deerfield Foundation

The Deerfield Foundation is a New York City-based not-for-profit organization whose mission is to improve health, accelerate innovation and promote human equity.

Read More Meet the Foundation Team
---
Cure Campus

Cure is a 12-story innovation campus in New York City that intends to bring together innovators from academia, government, industry, and the not-for-profit sectors to advance human health and accelerate the fight against disease.

Read More Join the Cure Email List
Cure Programming

Cure has a series of expert lectures intended to advance thought in healthcare, management, innovation, policy, and other relevant subjects. This fosters growth and education for those at Cure and its guests.

Events at the Cure

Deerfield Provides $125 million Debt Financing to Tris Pharma

Deerfield provides growth capital financing to Tris Pharma

New York, New York – October 4, 2018 – Deerfield announced today it provided $125 million to refinance existing debt and provide growth capital to Tris Pharma, Inc. This financing allows Tris to expand its branded pharmaceutical portfolio with a particular focus on Attention Deficit Hyperactivity Disorder (ADHD), launch and promote new products and continue development of its drug development platform.

In addition to the financing, Deerfield and Tris plan to enter into a product development agreement to leverage Tris’ proprietary drug delivery technology.

“Deerfield has partnered with Tris to provide a solution to address all our capital needs in a manner that allows Tris to fully focus on rapidly growing our branded ADHD business and expanding our R&D commitment,” stated Ketan Mehta, president and chief executive officer of Tris. “Additionally, by leveraging our drug delivery technology in partnership with Deerfield, we benefit from Deerfield’s expertise and capabilities.”

“This financing provides a solid foundation upon which Tris can promote and launch existing and new products, and we look forward to its success. Furthermore, Deerfield is delighted to collaborate with Tris’ strong management team as a long-term partner, and to develop new drugs that can be delivered through the company’s proprietary technology” stated Jim Flynn, Deerfield’s managing partner.

About Deerfield

Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.

For more information, please visit www.deerfield.com

Contacts

Deerfield Management
Company Karen Heidelberger, 212-551-1600
[email protected]